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Abstract
Hyperphosphatemia is associated with mortality in patients with chronic kidney disease, and
is common in critically ill patients with acute kidney injury (AKI); however, its clinical implica-
tion in these patients is unknown. We conducted an observational study in 1144 patients
(mean age, 63.2 years; male, 705 [61.6%]) with AKI who received continuous renal replace-
ment therapy (CRRT) between January 2009 and September 2016. Phosphate levels were
measured before (0 h) and 24 h after CRRT initiation. We assessed disease severity using
various clinical parameters. Phosphate at 0 h positively correlated with the Acute Physiology
and Chronic Health Evaluation II (APACHE II; P < 0.001) and Sequential Organ Failure
Assessment (SOFA; P < 0.001) scores, and inversely with mean arterial pressure (MAP;
P = 0.02) and urine output (UO; P = 0.01). In a fully adjusted linear regression analysis for
age, sex, Charlson comorbidity index (CCI), MAP, and estimated glomerular filtration rate
(eGFR), higher 0 h phosphate level was significantly associated with high APACHE II (P <
0.001) and SOFA (P = 0.04) scores, suggesting that phosphate represents disease severity.
A multivariable Cox model also showed that hyperphosphatemia was significantly associ-
ated with increased 28-day (HR 1.05, 95% CI 1.02–1.08, P = 0.001) and 90-day (HR 1.05,
95% CI 1.02–1.08, P = 0.001) mortality. Furthermore, patients with increased phosphate
level during 24 h were at higher risk of death than those with stable or decreased phosphate
levels. Finally, c-statistics significantly increased when phosphate was added to a model
that included age, sex, CCI, body mass index, eGFR, MAP, hemoglobin, serum albumin, C-
reactive protein, and APACHE II score. This study shows that phosphate is a potential bio-
marker that can reflect disease severity and predict mortality in critically ill patients receiving
CRRT.
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Introduction
Acute kidney injury (AKI) is common in critically ill patients. Approximately 5% of patients
with AKI in the intensive care unit (ICU) require renal replacement therapy (RRT), [1] and
these patients are more likely to have higher mortality and to progress to chronic kidney dis-
ease (CKD) [2] than those without AKI [3–5]. Thus, identification of risk factors is important
for predicting adverse outcomes. However, there is no single biomarker to reliably establish
cost-efficient risk stratification in this devastating condition.
Electrolyte and mineral imbalances are common even in patients receiving RRT. Distur-
bances in the regulatory mechanisms can result in significant consequences, especially in criti-
cally ill patients [6]. Phosphate is the most abundant intracellular anion in the body and is an
important component in multiple physiologic processes affecting many different organ sys-
tems [7]. Elevated serum phosphate levels are usually found in patients with moderate to
severe CKD, and are associated with cardiac valvular and vascular calcification, thus leading to
increased cardiovascular events and mortality [8, 9]. Hyperphosphatemia is also a common
condition in patients with AKI. It is likely due to decreased phosphate removal and secondary
hyperparathyroidism as a result of reduced kidney function [10, 11].
To date, the importance of hyperphosphatemia has been largely emphasized in patients
with CKD. However, studies on the clinical implication of hyperphosphatemia in critically ill
patients with AKI are lacking. We previously showed that increased phosphate levels predict
poor prognosis in patients with septic AKI receiving CRRT better than do other electrolytes
and minerals [10]. This finding led us to hypothesize that phosphate may correlate with the
degree of illness and serve as a marker of disease severity. Therefore, we conducted an observa-
tional study to evaluate the association between hyperphosphatemia and clinical parameters
reflecting disease severity, and to test whether phosphate levels are helpful in risk stratification
in these patients.
Materials and methods
Study population
Data were retrieved from the medical records of 1144 patients who received CRRT in the ICU
at Yonsei University Health System Severance Hospital and National Health Insurance Service
Medical Center Ilsan hospital between January 2009 and September 2016. Among 2391
patients who were initially assessed for study eligibility. Patients with stage 2 according to the
Acute Kidney Injury Network (AKIN) criteria [12] or more (>2-fold increase in the serum
creatinine or urine output [UO]<0.5 mLkg-1h-1 for 12 h) were eligible for the study. We
excluded patients who met the following criteria: age<18 years, pregnancy or lactation, his-
tory of CKD or dialysis or CRRT before the study, postrenal obstruction and prior kidney
transplantation. Thus, a total of 1144 patients were included in the analysis.
The study was approved by Yonsei University Health System, Severance Hospital, Institu-
tional Review Board and followed the provisions of the Declaration of Helsinki (approval no.
4-2016-1073). Because the current study was a retrospective, medical-record-based study and
the study subjects were de-identified, the board waived the need for written consent from the
patients. (Fig 1)
Clinical and biochemical data collection
Before starting CRRT, demographic and clinical data including age, sex, body mass index, and
comorbidities were recorded. Phosphate levels were measured before starting CRRT (0 h) and
24 h after CRRT initiation. We also collected the following biochemical laboratory data at 0 h:
Phosphate as a biomarker in acute kidney injury patients undergoing continuous renal replacement therapy
PLOS ONE | https://doi.org/10.1371/journal.pone.0191290 February 7, 2018 2 / 16
hemoglobin, white blood cell, serum creatinine, albumin, bicarbonate, potassium, lactate,
aspartate aminotransferase, alanine transaminase, and total bilirubin levels. The reference
range of phosphate level was 2.5–4.5 mg/dL, and hyperphosphatemia was defined as phosphate
level>4.5 mg/dL. We also collected data for age-adjusted Charlson comorbidity index (CCI),
Sequential Organ Failure Assessment (SOFA) score, and Acute Physiology and Chronic
Health Evaluation II (APACHE II) score.
Disease severity was assessed by using various clinical parameters: SOFA score, APACHE II
score, mean arterial pressure (MAP), UO, norepinephrine dose, C-reactive protein (CRP), and
lactate.
CRRT protocol
Upon the development of AKI in ICU patients, nephrologists decided whether or not to initiate
CRRT in those who were critically ill. General indications were sustained oliguria, uncontrolled
volume overload, intractable hyperkalemia or metabolic acidosis. Patients received continuous
veno-venous haemodiafiltration through the internal jugular, subclavian, or femoral vein using
the multiFiltrate (Fresenius Medical Care, Bad Homburg, Germany) or the Prismaflex (Baxter
International Inc. Lundia AB, Sweden) machine. The applied dialyzers had a surface area of 1.0
to 1.4 m2 with a sieving coefficient for albumin and ß2-microglobulin of 0.001 and 0.58 to 0.65,
respectively. CRRT was started at a blood flow rate of 100 mL/min, and this was increased up to
150 mL/min. The total effluent volume as a sum of dialysis and replacement dose was targeted
to deliver35 mLkg-1h-1 in all patients. The mean duration of 1st CRRT was 40 hours.
Study endpoints
The study endpoint was death that occurred within 28 and 90 days of CRRT initiation.
Fig 1. Flow chart of patient selection. CRRT continuous renal replacement therapy, AKIN acute kidney injury network, CKD chronic kidney disease.
https://doi.org/10.1371/journal.pone.0191290.g001
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Statistical analysis
SPSS for Windows version 23.0 (IBM Corp., Armonk, NY, USA) was used for all statistical
analyses. Continuous variables with normal distribution were expressed as the
mean ± standard deviation and compared using the Student’s t-test or one-way analysis of var-
iance. Data with skewed distribution were presented as a median with interquartile range. Cat-
egorical variables were expressed as a number (percentage) and compared using the chi-
squared test. Variables that did not show normal distribution were compared using Mann-
Whitney test or Kruskal-Wallis test. The Kolmogorov-Smirnov test was used to examine the
normality of the distribution of parameters. Pearson’s correlation coefficient for normally dis-
tributed data and Spearman’s rank correlation coefficient for skewed data were determined to
examine association between clinical parameters and disease severity score systems such as
APACHE II and SOFA scores. We further conducted multiple linear regression analysis to
delineate the relationship between phosphate and disease severity. We used R software (ver-
sion 2.12.1; R Foundation for Statistical Computing) for cubic spline curves analysis. The
smoothHR package was used to provide hazard ratio curves that allows for nonlinear relation-
ship between predictor and survival. Cumulative patient survival curves were derived using
the Kaplan-Meier method, and differences between curves were analyzed by log-rank test. Cox
proportional hazards models were constructed to identify independent association between
phosphate level and mortality. Variables with P 0.10 in univariate analyses and clinically
important variables were entered into the models. Results were presented as hazard ratio (HR)
and 95% confidence interval (CI). Violation of the proportional hazards assumption was tested
by means of inspection of log (-log [survival]) curves. We used R software (version 2.12.1; R
Foundation for Statistical Computing) for cubic spline curves analysis. The smoothHR package
was used to provide hazard ratio curves that allows for nonlinear relationship between predic-
tor and survival. The smoothHR contains functions that provide point wise estimates of Cox
model HR curve for continuous predictors as well as the corresponding confidence limits. We
also categorized patients into three groups according to the changes in phosphate levels
between 0h and 24h and compared death rates and mortality risk using multivariable Cox
models. In addition, Harrell’s C index was calculated to compare the discriminatory ability.
Variables were sequentially entered in 3 models. Model 1 included age, sex, CCI, BMI, urine
output (2 h), MAP, hemoglobin, serum albumin, and CRP. In model 2, SOFA score or
APACHE II score was added to Model 2. Finally, serum phosphate was additionally included
in Model 3. Furthermore, receiver operating characteristic (ROC) curve analysis was per-
formed to evaluate the prognostic value of phosphate level for mortality using R package sur-
vival ROC, version 2.12.1 (R Foundation for Statistical Computing). We measured the AUC;
AUCs were calculated and compared using DeLong’s method performed within the R package,
pROC. All probabilities were 2 tailed, and the level of statistical significance was defined as
P< 0.05.
Results
Baseline characteristics
Table 1 presents the baseline clinical characteristics and laboratory findings of all patients. The
most common cause for CRRT was sustained oliguria. The mean age of the participants was
63.2 ± 14.4 years, and 705 (61.6%) were male. Among the 1144 patients, 398 (34.8%) had dia-
betes and 186 (16.3%) had heart failure. The mean creatinine levels at admission to hospital
and at the time of CRRT initiation were 1.0 (0.7–1.3) and 2.7 ± 1.6 mg/dL, respectively. The
mean CCI was 3.2 ± 2.3. The mean SOFA score and APACHE II score was 12.1 ± 3.6 and
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Table 1. Baseline characteristics.
Patient Characteristics Total
(n = 1144)
Survivors
(n = 323)
Non-survivors
(n = 821)
P
Age (years) 63.2 ± 14.4 62.6 ± 15.1 63.4 ± 14.1 0.62
Male (%) 705 (61.6) 196 (60.7) 509 (62.0) 0.36
Hypertension (%) 601 (52.5) 204 (63.2) 397 (48.4) <0.001
Diabetes mellitus (%) 398 (34.8) 131 (32.9) 267 (32.6) 0.01
Heart failure (%) 186 (16.3) 58 (18.0) 128 (15.6) 0.19
Myocardial infarction (%) 112 (9.8) 36 (11.1) 76 (9.3) 0.20
Cerebrovascular disease (%) 114 (10.0) 37 (11.5) 77 (9.4) 0.17
COPD (%) 80 (7.0) 29 (9.0) 51 (6.2) 0.07
MV (%) 898 (78.5) 217 (67.2) 681 (83.0) <0.001
CCI 3.2 ± 2.3 2.7 ± 2.1 3.4 ± 2.3 <0.001
Cause of AKI 0.15
Sepsis 798 (69.8) 213 (65.9) 585 (71.3) 0.05
Nephrotoxin 37 (3.2) 13 (4.0) 24 (2.9) 0.22
Ischemia 98 (8.6) 26 (8.0) 72 (8.8) 0.40
Surgery 94 (8.2) 36 (11.1) 58 (7.1) 0.02
Others 117 (10.2) 35 (10.8) 82 (10.0) 0.37
Cause of CRRT 0.04
Volume overload (%) 160 (13.9) 55 (17.0) 105 (12.8) 0.04
Metabolic acidosis (%) 242 (21.2) 55 (17.0) 187 (22.8) 0.02
Hyperkalemia (%) 58 (5.1) 12 (3.7) 46 (5.6) 0.12
Uremia (%) 115 (10.1) 37 (11.5) 78 (9.5) 0.19
Oliguria (%) 294 (25.7) 93 (28.8) 201 (24.5) 0.08
Others (%) 275 (24.0) 71 (22.0) 204 (24.8) 0.17
Duration from diagnosis of AKI to CRRT (h) 1.1 [0.3–5.4] 0.9 [0.1–2.6] 1.3 [0.3–6.7] 0.01
AKIN stages 0.46
Stage 2 (%) 298 (26.0) 83 (25.7) 215 (26.2)
Stage 3 (%) 846 (74.0) 240 (74.3) 606 (73.8)
BMI (kg/m2) at ICU admission 23.8 ± 4.6 24.4 ± 4.3 23.6 ± 4.7 0.01
SOFA score 12.1 ± 3.6 10.2 ± 3.4 12.9 ± 3.3 <0.001
APACHE II score 27.3 ± 8.0 25.0 ± 7.9 28.2 ± 7.8 <0.001
SBP (mmHg) 112.0 ± 21.2 118.3 ± 21.2 109.5 ± 20.6 <0.001
DBP (mmHg) 60.3 ± 14.2 62.8 ± 14.5 59.4 ± 14.0 <0.001
MAP (mmHg) 77.4 ± 14.6 81.3 ± 15.2 75.9 ± 14.1 <0.001
Hemoglobin (g/dL) 9.6 ± 2.2 10.0 ± 2.3 9.5 ± 2.2 <0.001
White blood cell (μL) 11660 [6452–18645] 13385 [9035–20327] 11095 [5247–17910] <0.001
Albumin (g/dL) 2.6 ± 0.6 2.8 ± 0.6 2.5 ± 0.5 <0.001
Potassium (mEq/L) 4.7 ± 1.1 4.7 ± 1.0 4.7 ± 1.1 0.69
Bicarbonate (mEq/L) 16.9 ± 5.7 17.0 ± 5.1 16.9 ± 6.0 0.71
BUN (mg/dL) 55.8 ± 30.0 51.5 ± 27.3 57.5 ± 30.8 0.003
Phosphate (mg/dL) 5.7 ± 2.4 5.4 ± 2.4 5.9 ± 2.4 <0.001
Creatinine (mg/dL) 2.7 ± 1.6 3.0 ± 1.9 2.6 ± 1.5 <0.001
CRRT dose (ml/kg) 36.5 ± 4.8 36.3 ± 5.0 36.8 ± 4.7 0.001
(Continued)
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27.3 ± 8.0, respectively. The MAP at 0 h was 77.4 ± 14.6 mmHg. A total of 898 (78.5%) patients
received mechanical ventilation. The mean white blood cell counts and CRP levels were 11,660
(6452–18,645)/μL and 78.7 (21.0–170.9) mg/L, respectively (Table 1). The mean phosphate
level at 0h was 5.7 ± 2.4 mg/dL. Hyperphosphatemia was found in 721 (67.5%) patients before
starting CRRT, and remained in 399 (40.6%) at 24 h after CRRT initiation. In contrast, 35
(3.3%) and 115 (11.7%) patients had hypophosphatemia at 0 and 24 h, respectively.
Correlation between phosphate levels and disease severity
The SOFA and APACHE II score systems are well-validated tools that can assess disease sever-
ity and predict clinical outcome in critically ill patients. Thus, we tested whether phosphate
can reflect disease severity. Phosphate level significantly correlated with the APACHE II
(P< 0.001) and SOFA (P< 0.001) scores. We then further investigated the independent asso-
ciation of phosphate level with the SOFA and APACHE II scores. In a multivariable linear
regression analysis after adjustment for age, sex, CCI, MAP, and urine volume, phosphate lev-
els were significantly associated with the SOFA (β = 0.10, P = 0.02) and APACHE II (β = 0.58,
P< 0.001) scores (Table 2).
Hyperphosphatemia predicts adverse outcomes
Among the 1144 patients, 710 deaths (62.1%) and 821 deaths (71.8%) occurred during 28 and
90 days, respectively. To delineate the association between phosphate and mortality, we con-
structed stepwise multivariable Cox models. In all three models, phosphate levels were signifi-
cantly associated with an increased risk of death. The fully adjusted model (model 3) revealed
Table 1. (Continued)
Patient Characteristics Total
(n = 1144)
Survivors
(n = 323)
Non-survivors
(n = 821)
P
CRP (mg/L) 78.7 [21.0–70.9] 74.5 [19.2–164.2] 80.4 [21.8–174.7] 0.35
Data are expressed as mean ± standard deviations, median (interquartile range), or number (%).
All laboratory measurements were done at 0 h (before starting CRRT)
Abbreviations: COPD Chronic obstructive pulmonary disease, CCI Charlson comorbidity index, BMI Body mass index, AKIN Acute kidney injury criteria, ICU Intensive
care unit, CRRT Continuous renal replacement therapy, eGFR estimated glomerular filtration rate, SOFA Sequential Organ Failure Assessment Score, APACHE II Acute
Physiology and Chronic Health Evaluation II, SBP Systolic blood pressure, DBP Diastolic blood pressure, MAP Mean arterial pressure, CRP C-reactive protein
https://doi.org/10.1371/journal.pone.0191290.t001
Table 2. Univariate and multivariate associations between phosphate level at 0h and disease severity.
SOFA score APACHE II score
Univariate Multivariate Univariate Multivariate
Variables β P β P β P β P
Age -0.03 <0.001 -0.03 <0.001 0.07 <0.001 0.07 <0.001
Sex -0.65 0.002 -0.55 0.01 -1.58 0.001 -1.20 0.02
CCI 0.13 0.004 0.09 0.05 0.04 0.69 -0.04 0.70
MAP (mmHg) -0.02 0.01 -0.02 0.04 -0.06 <0.001 -0.05 0.01
Urine output (2 h) -0.01 0.001 -0.01 <0.001 -0.01 0.01 -0.004 0.13
Phosphate (mg/L) 0.16 <0.001 0.10 0.02 0.59 <0.001 0.58 <0.001
Abbreviations: CCI Charlson comorbidity index, MAP Mean arterial pressure, SOFA Sequential Organ Failure Assessment Score, APACHE II Acute Physiology and
Chronic Health Evaluation II
https://doi.org/10.1371/journal.pone.0191290.t002
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that the HRs for 28- and 90-day mortality were 1.05 (per 1 mg/dL increase, 95% CI, 1.02–1.08;
P = 0.001) and 1.05 (per 1 mg/dL increase, 95% CI, 1.02–1.08; P = 0.001), respectively
(Table 3). Cubic spline curves after the full adjustment also showed an almost linear relation-
ship between phosphate and mortality. This association was consistently observed when phos-
phate level at 24 h was entered into the analyses (Fig 2).
Mortality risk according to changes in phosphate levels during 24 h
Next, we evaluated changes in phosphate levels during 24 h and further explored the signifi-
cance of phosphate in these patients (S3 Table). There were 222 patients who had increased
phosphate levels during 24 h. The 28- and 90-day deaths occurred more in these patients as
compared with those with stable or decreased phosphate levels (28-day, 71.6% vs. 56.6%,
P< 0.001; 90-day, 76.6% vs. 69.0%, P = 0.02) (Table 4). The crude HRs for 28- and 90-day
mortality were 1.66 (95% CI, 1.32–2.08; P< 0.001) and 1.57 (95% CI, 1.27–1.94; P< 0.001),
respectively. A Kaplan-Meier curve also confirmed that time to death was significantly shorter
in patients with increased phosphate levels (Fig 3). In a Cox regression model after full adjust-
ment, patients with increased phosphate levels conferred 1.51-fold (95% CI, 1.24–1.86;
P< 0.001) and 1.50-fold increased risks of 28- and 90-day mortality (95% CI, 1.24–1.82;
P< 0.001) as compared with those with decreased phosphate levels (Table 5).
We further examined the change of disease severity markers according to phosphate
changes. The number of available data differed among the parameters. SOFA score, APACHE
II score, potassium, bicarbonate, norepinephrine dose and MAP were fully evaluated except
for those who expired within 24 hours. However, lactate (n = 178) and CRP level (n = 225)
were not fully evaluated. The number of patients whose relevant data were fully available at
24h was 178. There was an improvement in SOFA score (P = 0.03), APACHE II score
(P< 0.001), acidosis (P = 0.01), lactate level (P = 0.01), and CRP level (P = 0.004) in patients
with decreased phosphate levels, whilst these parameters remained similar or worsened in
those with increased phosphate levels (S1 Table).
Additive prognostic value of phosphate for mortality prediction
To confirm the validity of phosphate as a useful biomarker, we calculated Harrell’s C-index for
each multivariate Cox regression model. The c-statistics of model 1 for the prediction of
28-day mortality was 0.686 (95% CI, 0.648–0.722). In model 2 after additional adjustment for
Table 3. Cox proportional hazard regression analysis for 28- and 90-day mortality.
Phosphate at 0h as a continuous variable
(Per 1 mg/dL increase)
28-day 90-day
Deaths (n, %) 710 (62.1%) 821 (71.8%)
HR (95% CI) P HR (95% CI) P
Model 1 1.06 (1.03–1.09) <0.001 1.06 (1.03–1.09) <0.001
Model 2 1.07 (1.04–1.10) <0.001 1.06 (1.03–1.09) <0.001
Model 3 1.05 (1.02–1.08) 0.001 1.05 (1.02–1.08) 0.001
Model 1: unadjusted.
Model 2: age, sex, and BMI at ICU admission.
Model 3: model 2 + CCI, SOFA score, urine output (2 h).
Abbreviation: HR Hazard ratio, CI Confidence interval, BMI Body mass index, ICU Intensive care unit, CCI Charlson
comorbidity index, SOFA Sequential Organ Failure Assessment
https://doi.org/10.1371/journal.pone.0191290.t003
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SOFA score, the c-statistics were significantly increased as compared with model 1 (0.769; 95%
CI, 0.737–0.802; P<0.001). Adding phosphate to model 2 also further improved the predictive
ability (0.798; 95% CI, 0.762–0.823; P< 0.001 vs. model 1 and P = 0.042 vs. model 2). This
association was also found for 90-day mortality. In addition, the results remained unaltered
when SOFA score was replaced with APACHE II score. These findings were further confirmed
by ROC curve analyses. The area under the curve (AUC) was the largest in a model that
included phosphate in addition to conventional variables and SOFA score (Fig 4). The
Fig 2. Cubic spline analysis of the associations between phosphate levels and 28- and 90-day mortality. Hazard ratios (HRs) were adjusted for age, sex, body mass
index (BMI), Charlson comorbidity index (CCI), Sequential Organ Failure Assessment (SOFA) score, urine output (UO), albumin, and mean arterial pressure (MAP).
Line represents HR. Shaded area represents 95% CI for the HR.
https://doi.org/10.1371/journal.pone.0191290.g002
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improved predictive ability of phosphate was more evident when phosphate level at 24 h was
entered into the analyses (Fig 5).
Residual hyperphosphatemia has prognostic value in predicting mortality
As described earlier, 222 (40.6%) patients still had hyperphosphatemia at 24 h after CRRT ini-
tiation. We evaluated whether residual hyperphosphatemia can predict mortality. Similar to
the analysis with phosphate level at 0 h, phosphate level at 24 h was significantly associated
with a 1.15-fold increased risk of 28-day (HR, 1.15; 95% CI, 1.09–1.20; P< 0.001) and 90-day
(HR, 1.15; 95% CI, 1.09–1.20; P< 0.001) mortality (S2 Table). In addition, the c-statistics of a
model with serum phosphate significantly improved as compared with a model with
Table 4. Death rates according to changes in phosphate levels between 0 and 24 h.
Overall (n = 964) Group 1 (n = 466) Group 2 (n = 276) Group 3(n = 222) P
28-day mortality 579(60.1%) 254(54.5%) 166(60.1%) 159(71.6%) <0.001
0h P < 2.5 mg/dL 13(39.4%) 0(0%) 2(25.0%) 11(44.0%) 0.30
0h P 2.5–4.5 mg/dL 159(56.2%) 26(51.0%) 65(52.4%) 68(63.0%) 0.19
0h P 4.5 mg/dL 407(62.8%) 228(54.9%) 99(68.8%) 80(89.9%) <0.001
90-day mortality 682(70.7) 313(67.2%) 199(72.1%) 170(76.6%) 0.03
0h P < 2.5 mg/dL 17(51.5%) 0(0%) 4(50.0%) 13(52.0%) 0.62
0h P 2.5–4.5 mg/dL 186(65.7%) 29(56.9%) 81(65.3%) 76(70.4%) 0.24
0h P 4.5 mg/dL: 479(73.9%) 284(68.4%) 114(79.2%) 81(91.0%) <0.001
Data are expressed as numbers (%).
Group 1 (phosphate decrease group), -1.3 mg/dL decrease; group 2 (stable group), -1.3 to 0 mg/dL decrease; group 3 (phosphate increase group)
https://doi.org/10.1371/journal.pone.0191290.t004
Fig 3. Kaplan-Meier plots for 28- and 90-day mortality according to phosphate change. Group 1 (phosphate decrease group),-1.3 mg/dL decrease; group 2 (stable
group), -1.3 to 0 mg/dL decrease; group 3 (phosphate increase group).
https://doi.org/10.1371/journal.pone.0191290.g003
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conventional variables. The improved predictive ability of phosphate was more evident on
ROC curve analysis when the phosphate level at 24 h was entered (Fig 4).
Discussion
In this study, we investigated whether phosphate can serve as a biomarker of disease severity
and a predictor of mortality in critically ill patients receiving CRRT. We found that phosphate
level well correlates with APACHE II and SOFA scores, which are two representative scoring
systems that can reflect a life-threatening condition in patients in the ICU. In addition, we
demonstrated that serum phosphate is significantly associated with mortality. The prognostic
value of phosphate was further verified by different statistical methods such as conventional
Cox regression models, c-statistics analysis, and ROC curve analysis. Our robust findings sug-
gest that phosphate is indeed a good biomarker of disease severity and is useful in risk stratifi-
cation for prediction of adverse outcomes in critically ill patients.
Disturbances in electrolyte and mineral homeostasis commonly occur in patients in the
ICU. These are also frequently found even in patients receiving RRT.[10] However, whether
abnormalities of electrolytes and minerals are associated with disease severity is not known.
We clearly showed that phosphate level significantly correlates with various clinical parameters
related to disease severity. Interestingly, besides SOFA and APACHE II scores, high serum
phosphate also highly associates with low blood pressure, decreased kidney function, low UO,
and high acidosis level. All these parameters represent the degree of illness in the critically ill
condition. In contrast, this association was not observed or weak for other electrolytes and
minerals such as sodium, potassium, and calcium. Although phosphate is well cleared by dialy-
sis therapy, we found that residual hyperphosphatemia remained in a substantial portion of
patients at 24 h after CRRT. We further demonstrated that this residual hyperphosphatemia
also associates with the SOFA and APACHE II scores when the phosphate level at 24 h was
used in the analysis. Taken together, these findings suggest that phosphate deserves attention
and can be used as a potential marker of disease severity.
We also validated the role of phosphate as a biomarker in predicting future adverse out-
comes. Our previous work showed that hyperphosphatemia is significantly associated with an
increased risk of death.[10] In this study, we substantiated this finding in a larger cohort by
Table 5. Cox proportional hazard regression analysis for 28- and 90-day mortality according to changes in phos-
phate levels between 0 and 24 h.
Phosphate as a categorical variable
( -1.3 decrease vs. increase)a
28-day 90-day
Deaths (n, %) 710 (62.1%) 821 (71.8%)
HR (95% CI) P HR (95% CI) P
Model 1 1.54 (1.26–1.88) <0.001 1.47 (1.22–1.77) <0.001
Model 2 1.55 (1.27–1.90) <0.001 1.47 (1.21–1.78) <0.001
Model 3 1.51 (1.24–1.86) <0.001 1.50 (1.24–1.82) <0.001
a. Phosphate change “ -1.3 mg/dL decrease” group is a referent.
Model 1: unadjusted.
Model 2: age, sex, and BMI at ICU admission.
Model 3: model 2 + CCI, SOFA score, 2 h urine output before CRRT (mL).
Abbreviation: HR Hazard ratio, CI Confidence interval, BMI Body mass index, ICU Intensive care unit, CCI Charlson
comorbidity index, SOFA Sequential Organ Failure Assessment.
https://doi.org/10.1371/journal.pone.0191290.t005
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using diverse analytical methods. It should be noted that adding phosphate to conventional
models significantly improved the predictive ability as compared with the models with SOFA
and APACHE II scores, although the extent of the improved c-statistics and AUC was small.
However, it is well known that the SOFA or APACHE II score encompasses almost all parame-
ters that reflect disease severity in the critically ill condition. In fact, these two scoring systems
involve a variety of organ compromises, including the cardiovascular, respiratory, hepatic,
renal, and central nervous systems. Therefore, finding a novel biomarker beyond the two sys-
tems is highly challenging. Many studies have identified biomarkers in the circulation or urine
to date; however, no biomarker is superior to these two scoring systems in predicting clinical
adverse outcomes. For example, recent studies have suggested that urinary biomarkers such as
kidney injury molecule-1 (KIM-1), N-acetyl-(D)-glucosaminidase (NAG), and neutrophil gela-
tinase-associated lipocalin (NGAL) are helpful in diagnosing AKI and in predicting mortality
Fig 4. Receiver-operating characteristic plots representing the area under the curve (AUC) for the prediction of 28- and 90-daay
mortality according to 0 h phosphate. The AUCs for 28- (A) and 90- day (B) mortality using models with SOFA score; The AUCs for 28-
(C) and 90- day (D) mortality using models with APACHE II score. Comparison P values were calculated.
https://doi.org/10.1371/journal.pone.0191290.g004
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in various clinical settings [13–15]. Nevertheless, none of these predicts better adverse out-
comes than the APACHE II score.
Cost-effectiveness is another merit of using phosphate as a biomarker. In Korea, the cost
for the measurement of NGAL is 25 times higher than that for serum phosphate. Given the
considerable medical cost in the management of critically ill patients in the ICU, incorporation
of phosphate into risk stratification can be a cost-saving strategy. Taken all findings into
account, phosphate should be highlighted as a potential biomarker of disease severity and clin-
ical adverse outcomes.
In this study, we showed that residual hyperphosphatemia still has prognostic value. Nota-
bly, patients with a reduction in phosphate levels during 24 h had a better survival than those
Fig 5. Receiver-operating characteristic plots representing the area under the curve (AUC) for the prediction of 28- and 90-day mortality according to
24 h phosphate. The AUCs for 28- (A) and 90- day (B) mortality using models with SOFA score; The AUCs for 28- (C) and 90- day (D) mortality using
models with APACHE II score. Comparison P values were calculated.
https://doi.org/10.1371/journal.pone.0191290.g005
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with stable or increased phosphate levels. This finding raises an important question on
whether phosphate level should be lowered by dialysis or pharmacologic treatment in critically
ill patients. Phosphate toxicity has been well recognized particularly in patients with CKD.
Many epidemiologic studies have consistently shown that increased phosphate level is signifi-
cantly associated with cardiovascular events and mortality in these patients [16–18]. However,
there is much controversy about whether pharmacologic treatment is beneficial in improving
mortality [19, 20]. The results of these studies should be interpreted with caution because the
achieved levels of phosphate were not analyzed. In acute injury settings, phosphate can simply
be a marker or mediator of direct toxicity. Upon cell injury, many harmful signals such as
inflammatory cytokines are also released. Therefore, phosphate may not be the major culprit
in the development of fatal events. Of note, increased phosphate level can elevate the fibroblast
growth factor-23 (FGF23) level [21, 22]. FGF23 has emerged as a powerful biomarker of car-
diovascular disease and death in patients with CKD [21, 23–25]. It is also reported to have
direct toxic effects on the cardiovascular system [25–27] and to be associated with adverse out-
comes in human studies with a small sample size [21, 28, 29]. By contrast, it is possible that
phosphate released from dead cells is directly toxic to adjacent cells and tissues. In fact, Papa
and Skulachev demonstrated that phosphate influx into cells causes mitochondrial damage
and produces reactive oxygen in vivo [30]. Given the complex relationship between phosphate
and cell death, further studies are required to elucidate the role of phosphate and the effect of
phosphate-lowering treatment in critically ill patients. In addition, another possible mediator
of mortality among the patients with hyperphosphatemia in the study is reduction of ionized
blood calcium levels with the associated risks of neurological and cardiovascular complications
such as arrhythmias.
Several limitations must be considered in this study. First, because this is a retrospective
observational study, potential bias can hamper interpretation of our findings. In particular,
hyperphosphatemia can occur in patients with late application of CRRT. Such different
time-points of initiating CRRT can result in length-time bias. In this study, most patients
started to receive CRRT within 72 hours after ICU admission. Therefore, hyperphosphatemia
is unlikely caused by late treatment. Nevertheless, our observational study cannot entirely
exclude length-time bias. Second, although the prescribed effluent dose was targeted to deliver
35 mLkg-1h-1, it is unknown whether all patients reached this target. In real clinical prac-
tice, ensuring target volume as it is prescribed is almost impossible because of many technical
issues such as clotting, poor blood flow, and recirculation. To minimize this, CRRT circuit was
changed every 48 hours in our center regardless of clotting status in the dialyzer filter. Third,
we did not have data for parathyroid hormone, FGF23, and 1,25-dihydroxyvitamin D3 levels.
In addition, other conditions that could affect phosphate level before CRRT initiation such as
diet or nutritional supplement were not well captured. Because these parameters closely in-
teract with phosphate, it would be helpful to understand the complex relationship between
phosphate and its associated factors in the development of adverse outcomes if these were inte-
grated into the analysis. Lastly, the database does not include data for recently developed bio-
markers such as KIM-1, NAG, or NGAL; thus, comparative analysis between phosphate and
these markers are not feasible. Forth, we showed that the predictability of phosphate for mor-
tality was slightly better than that of the SOFA and APACHE II scores. However, the differ-
ences in AUCs were so marginal and whether such subtle but statistically significant difference
can have clinical impact has been under debate [31–33]. As mentioned earlier, these two scor-
ing systems are the most powerful assessment tools that can predict adverse outcomes in
patients in the ICU, thus improving predictive ability using some potential markers is not easy
beyond these two scoring systems. In this regard, phosphate should receive more attention
given its advantages of predictability and cost-effectiveness. In conclusion, we demonstrated
Phosphate as a biomarker in acute kidney injury patients undergoing continuous renal replacement therapy
PLOS ONE | https://doi.org/10.1371/journal.pone.0191290 February 7, 2018 13 / 16
that phosphate is a potential biomarker that can reflect disease severity and predict mortality
in critically ill patients receiving CRRT. Future studies should address whether phosphate
should be incorporated into risk stratification and whether lowering the phosphate level can
reduce mortality in these patients.
Supporting information
S1 Table. Changes of disease severity markers according to phosphate changes.
(DOCX)
S2 Table. Cox proportional hazard regression analysis for 28- and 90-day mortality in 399
patients who survived 24 h after continuous renal replacement therapy initiation.
(DOCX)
S3 Table. Baseline characteristics according to changes in phosphate levels between 0 and
24 h.
(DOCX)
Author Contributions
Conceptualization: Seung Hyeok Han.
Data curation: Jaeyeol Kwon, Ea Wha Kang.
Formal analysis: Seohyun Park.
Investigation: Jong Hyun Jhee.
Methodology: Hae-Ryong Yun.
Project administration: HyoungNae Kim.
Supervision: Youn Kyung Kee, Tae-Hyun Yoo.
Validation: Chang-Yun Yoon.
Visualization: Tae-Ik Chang.
Writing – original draft: Su-Young Jung.
Writing – review & editing: Jung Tak Park, Shin-Wook Kang, Seung Hyeok Han.
References
1. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al. Acute renal failure in critically
ill patients: a multinational, multicenter study. JAMA. 2005; 294(7):813–8. https://doi.org/10.1001/jama.
294.7.813 PMID: 16106006.
2. Chawla LS, Kimmel PL. Acute kidney injury and chronic kidney disease: an integrated clinical syn-
drome. Kidney Int. 2012; 82(5):516–24. https://doi.org/10.1038/ki.2012.208 PMID: 22673882.
3. Investigators RRTS, Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, et al. Intensity of continuous
renal-replacement therapy in critically ill patients. N Engl J Med. 2009; 361(17):1627–38. https://doi.org/
10.1056/NEJMoa0902413 PMID: 19846848.
4. Gaudry S, Hajage D, Schortgen F, Martin-Lefevre L, Pons B, Boulet E, et al. Initiation Strategies for
Renal-Replacement Therapy in the Intensive Care Unit. N Engl J Med. 2016; 375(2):122–33. https://
doi.org/10.1056/NEJMoa1603017 PMID: 27181456.
5. Demirjian S, Chertow GM, Zhang JH, O’Connor TZ, Vitale J, Paganini EP, et al. Model to predict mortal-
ity in critically ill adults with acute kidney injury. Clin J Am Soc Nephrol. 2011; 6(9):2114–20. https://doi.
org/10.2215/CJN.02900311 PMID: 21896828; PubMed Central PMCID: PMCPMC3359007.
Phosphate as a biomarker in acute kidney injury patients undergoing continuous renal replacement therapy
PLOS ONE | https://doi.org/10.1371/journal.pone.0191290 February 7, 2018 14 / 16
6. Buckley MS, Leblanc JM, Cawley MJ. Electrolyte disturbances associated with commonly prescribed
medications in the intensive care unit. Crit Care Med. 2010; 38(6 Suppl):S253–64. https://doi.org/10.
1097/CCM.0b013e3181dda0be PMID: 20502178.
7. Peppers MP, Geheb M, Desai T. Endocrine crises. Hypophosphatemia and hyperphosphatemia. Crit
Care Clin. 1991; 7(1):201–14. PMID: 2007215.
8. Foley RN. Phosphate levels and cardiovascular disease in the general population. Clin J Am Soc
Nephrol. 2009; 4(6):1136–9. https://doi.org/10.2215/CJN.01660309 PMID: 19423568.
9. Sullivan C, Sayre SS, Leon JB, Machekano R, Love TE, Porter D, et al. Effect of food additives on
hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial. JAMA.
2009; 301(6):629–35. https://doi.org/10.1001/jama.2009.96 PMID: 19211470.
10. Jung SY, Kim H, Park S, Jhee JH, Yun HR, Kim H, et al. Electrolyte and mineral disturbances in septic
acute kidney injury patients undergoing continuous renal replacement therapy. Medicine (Baltimore).
2016; 95(36):e4542. https://doi.org/10.1097/MD.0000000000004542 PMID: 27603344; PubMed Cen-
tral PMCID: PMCPMC5023866.
11. Ozmen S, Danis R, Akin D, Cil T, Yazanel O. Parathyroid hormone as a marker for the differential diag-
nosis of acute and chronic renal failure. Ren Fail. 2007; 29(4):509–12. https://doi.org/10.1080/
08860220701275006 PMID: 17497477.
12. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Net-
work: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007; 11(2):R31.
https://doi.org/10.1186/cc5713 PMID: 17331245; PubMed Central PMCID: PMCPMC2206446.
13. Liangos O, Perianayagam MC, Vaidya VS, Han WK, Wald R, Tighiouart H, et al. Urinary N-acetyl-beta-
(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes
in acute renal failure. J Am Soc Nephrol. 2007; 18(3):904–12. https://doi.org/10.1681/ASN.2006030221
PMID: 17267747.
14. Sanjeevani S, Pruthi S, Kalra S, Goel A, Kalra OP. Role of neutrophil gelatinase-associated lipocalin for
early detection of acute kidney injury. Int J Crit Illn Inj Sci. 2014; 4(3):223–8. https://doi.org/10.4103/
2229-5151.141420 PMID: 25337484; PubMed Central PMCID: PMCPMC4200548.
15. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A, Group NM-aI. Accuracy of neutro-
phil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a system-
atic review and meta-analysis. Am J Kidney Dis. 2009; 54(6):1012–24. https://doi.org/10.1053/j.ajkd.
2009.07.020 PMID: 19850388.
16. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x
phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney
Dis. 1998; 31(4):607–17. PMID: 9531176.
17. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4),
Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis
patients. J Am Soc Nephrol. 2001; 12(10):2131–8. PMID: 11562412.
18. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, et al. Serum phosphate
levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005; 16
(2):520–8. https://doi.org/10.1681/ASN.2004070602 PMID: 15615819.
19. Palmer SC, Gardner S, Tonelli M, Mavridis D, Johnson DW, Craig JC, et al. Phosphate-Binding Agents
in Adults With CKD: A Network Meta-analysis of Randomized Trials. Am J Kidney Dis. 2016; 68
(5):691–702. https://doi.org/10.1053/j.ajkd.2016.05.015 PMID: 27461851.
20. Isakova T, Gutierrez OM, Chang Y, Shah A, Tamez H, Smith K, et al. Phosphorus binders and survival
on hemodialysis. J Am Soc Nephrol. 2009; 20(2):388–96. https://doi.org/10.1681/ASN.2008060609
PMID: 19092121; PubMed Central PMCID: PMCPMC2637053.
21. Leaf DE, Wolf M, Waikar SS, Chase H, Christov M, Cremers S, et al. FGF-23 levels in patients with AKI
and risk of adverse outcomes. Clin J Am Soc Nephrol. 2012; 7(8):1217–23. https://doi.org/10.2215/
CJN.00550112 PMID: 22700885; PubMed Central PMCID: PMCPMC3408118.
22. Titan SM, Zatz R, Graciolli FG, dos Reis LM, Barros RT, Jorgetti V, et al. FGF-23 as a predictor of renal
outcome in diabetic nephropathy. Clin J Am Soc Nephrol. 2011; 6(2):241–7. https://doi.org/10.2215/
CJN.04250510 PMID: 20966122; PubMed Central PMCID: PMCPMC3052212.
23. Leaf DE, Jacob KA, Srivastava A, Chen ME, Christov M, Juppner H, et al. Fibroblast Growth Factor 23
Levels Associate with AKI and Death in Critical Illness. J Am Soc Nephrol. 2016. https://doi.org/10.
1681/ASN.2016080836 PMID: 28028134.
24. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor
23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008; 359(6):584–92. https://
doi.org/10.1056/NEJMoa0706130 PMID: 18687639; PubMed Central PMCID: PMCPMC2890264.
Phosphate as a biomarker in acute kidney injury patients undergoing continuous renal replacement therapy
PLOS ONE | https://doi.org/10.1371/journal.pone.0191290 February 7, 2018 15 / 16
25. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, et al. Fibroblast growth factor 23 and risks of
mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011; 305
(23):2432–9. https://doi.org/10.1001/jama.2011.826 PMID: 21673295; PubMed Central PMCID:
PMCPMC3124770.
26. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hyper-
trophy. J Clin Invest. 2011; 121(11):4393–408. https://doi.org/10.1172/JCI46122 PMID: 21985788;
PubMed Central PMCID: PMCPMC3204831.
27. Jimbo R, Kawakami-Mori F, Mu S, Hirohama D, Majtan B, Shimizu Y, et al. Fibroblast growth factor 23
accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. Kidney Int.
2014; 85(5):1103–11. https://doi.org/10.1038/ki.2013.332 PMID: 24088960.
28. Zhang M, Hsu R, Hsu CY, Kordesch K, Nicasio E, Cortez A, et al. FGF-23 and PTH levels in patients
with acute kidney injury: A cross-sectional case series study. Ann Intensive Care. 2011; 1(1):21. https://
doi.org/10.1186/2110-5820-1-21 PMID: 21906363; PubMed Central PMCID: PMCPMC3224491.
29. Ali FN, Hassinger A, Price H, Langman CB. Preoperative plasma FGF23 levels predict acute kidney
injury in children: results of a pilot study. Pediatr Nephrol. 2013; 28(6):959–62. https://doi.org/10.1007/
s00467-012-2395-2 PMID: 23314442.
30. Papa S, Skulachev VP. Reactive oxygen species, mitochondria, apoptosis and aging. Mol Cell Bio-
chem. 1997; 174(1–2):305–19. PMID: 9309704.
31. Baker SG, Schuit E, Steyerberg EW, Pencina MJ, Vickers A, Moons KG, et al. How to interpret a small
increase in AUC with an additional risk prediction marker: decision analysis comes through. Stat Med.
2014; 33(22):3946–59. https://doi.org/10.1002/sim.6195 PMID: 24825728; PubMed Central PMCID:
PMCPMC4156533.
32. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation.
2007; 115(7):928–35. https://doi.org/10.1161/CIRCULATIONAHA.106.672402 PMID: 17309939.
33. Gail MH. Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast
cancer risk. J Natl Cancer Inst. 2008; 100(14):1037–41. https://doi.org/10.1093/jnci/djn180 PMID:
18612136; PubMed Central PMCID: PMCPMC2528005.
Phosphate as a biomarker in acute kidney injury patients undergoing continuous renal replacement therapy
PLOS ONE | https://doi.org/10.1371/journal.pone.0191290 February 7, 2018 16 / 16
